| Date | Title | Description |
| 03.09.2024 | Pharmaceutical Market: Trends, Segmentation, and Growth Opportunities | Share
Tweet
Share
Share
Email
In recent years, the pharmaceutical market has witnessed remarkable growth and transformation, driven by technological advancements, evolving consumer needs, and the global push for better healthcare solutions.... |
| 08.08.2024 | Gilead quarterly profit beats Street estimates, revenue up 5% | Healthcare & PharmaceuticalsCommercial Strategy
Gilead quarterly profit beats Street estimates, revenue up 5%
By Deena BeasleyAugust 8, 20248:05 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Li... |
| 06.08.2024 | Зарядка по Wi-Fi | 65 нм, зато свои | Прививка от ВИЧ | Таблетка от старости | Титановое сердце
Итак, коллеги, в мире кардиологии снова шумиха. 9 июля сего года в Хьюстоне имплантировали первое в мире искусственное сердце без клапанов.
Речь идет о Total Artificial Heart (TAH) от компании BiVACOR - титановом устройстве... |
| 26.07.2024 | Taiwan's Military Evolution: Adapting to the Shadow of China | Taiwan stands at a crossroads. The island nation, self-governed yet claimed by China, is reshaping its military strategy. The annual Han Kuang exercises, which began on July 22, 2024, reflect a significant shift. Gone are the days of rehear... |
| 25.07.2024 | MoU signing between HCSA Community Services and Tzu-Chi Foundation (Singapore) to support Hepatitis C elimination initiative for former drug abusers in Singapore | SINGAPORE, July 25, 2024 /PRNewswire/ -- HCSA Community Services and Tzu-Chi Foundation (Singapore) today signed a Memorandum of Understanding (MoU) to formalise support for Phase 2 of the Educate, Test, Treat! (ETT) initiative, which has b... |
| 23.07.2024 | New 'vaccine-like' HIV drug could cost just US$40: Researchers | PARIS: A new "vaccine-like" HIV drug that currently costs over US$40,000 per person a year could be made for as little as US$40, researchers estimated on Tuesday (Jul 23).
The antiretroviral drug Lenacapavir, developed by US pharm... |
| 18.07.2024 | Research Identifies Blind Spots That Affect Quality of Life Among People with HIV in Singapore | Dedicated mobile app to encourage proactive management of physical health, mental well-being and chronic disease
SINGAPORE, July 18, 2024 /PRNewswire/ -- With the advancements in medical sciences, there is now very little difference between... |
| 08.07.2024 | Ligand to Acquire Apeiron Biologics, for $100M | Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a San Diego, CA-based biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines, acquired Apeiron Biologics AG, a Vienna, Austria-b... |
| 08.07.2024 | BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial | SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-bli... |
| 02.07.2024 | NACD Announces 10 Finalists for the 2024 DE&I Awards | WASHINGTON, July 2, 2024 /PRNewswire/ -- The National Association of Corporate Directors (NACD) announced today the 10 finalists for its 2024 Diversity, Equity & Inclusion (DE&I) Awards. The NACD DE&I Awards™, first launched in ... |
| 18.06.2024 | Axtria Announces its First Ignite Leadership Award Honorees | Award Honors Top Executives Fueling Innovation and Impact in the Life Sciences Industry
BERKELEY HEIGHTS, N.J., June 18, 2024 /PRNewswire/ -- Axtria, a global leader in cloud software and data analytics for the life sciences industry, has a... |
| 30.05.2024 | US, UK in focus as pharma companies eye $31 billion exports in FY25 | - |
| 02.05.2024 | Biotech Buyers Beware: 3 Stocks to Avoid The biotech industry is flourishing due to groundbreaking developments in cell and gene therapies and the rapid adoption of new technologies. However, not all ... | - |
| 27.04.2024 | India becoming attractive for clinical trials, says pharma industry leaders | - |
| 24.04.2024 | Govt expands committee for drugs, medical devices pricing reforms | - |
| 18.04.2024 | Gilead Sciences' $4 Million Grant for Viral Hepatitis Elimination in Asia | Gilead Sciences, in collaboration with the World Hepatitis Alliance, awarded a $4 million grant to support innovative projects addressing viral hepatitis in Asia. The grant aims to eliminate viral hepatitis by 2030 through community-led ini... |
| 17.04.2024 | GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA | — Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant —
– World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee –
— Vietnamese Organiz... |
| 17.04.2024 | GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN ASIA | — Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant —
– World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee –
— Indian Organizatio... |
| 15.04.2024 | GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KON... | -- Gilead Awards US$4 Million Globally (Excluding the United States) Through The Gilead ALL4LIVER Grant --
-- World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee --
-- Hong Kong Liv... |
| 15.04.2024 | GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA | – Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant –
– World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee –
– South Korea's Asso... |
| 15.04.2024 | Women of Influence: Health Care 2024 – Ileana Hernandez | - |
| 09.04.2024 | Rural COVID patients likelier to die after hospitalization | A new Mayo Clinic study finds rural COVID-19 patients were 22% likelier to die after a hospital stay than their urban counterparts and that disparities persisted despite the rollout of coronavirus vaccines.
Why it matters: The findings unde... |
| 09.04.2024 | Merck Life Science gets new MD | Merck has appointed Dhananjay Singh as Managing Director of Merck Life Science, in India. He takes over from Sreenath NS, who retires after 36 years with Merck in the country.
Also read:Merck, Novo Nordisk, Gilead, Biogen and more: Here are... |
| 25.03.2024 | Gilead Sciences Completes Acquisition of CymaBay, for Approximately $4.3 Billion | Gilead Sciences (Nasdaq: GILD), a Foster City, CA-based biopharmaceutical company, acquired CymaBay Therapeutics, Inc. (Nasdaq: CBAY), CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a Newark-based biopharmaceutical company focused on innovative... |
| 21.03.2024 | Scispot Welcomes Pharma Leader Dr. Sarah Warren to Advisory Board | Dr. Sarah Warren Joins Scispot to power Pharma expansion
Dr. Sarah Warren Joins Scispot as Scientific Advisor. Her appointment signals a significant step forward for Scispot, expanding its innovative offerings to the larger pharmaceutical c... |
| 21.03.2024 | Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Leading scientific, IT, and business innovators in the biopharma industry showca... |
| 18.03.2024 | Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer | SHANGHAI, March 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovativ... |
| 13.03.2024 | После вмешательства генпрокурора РФ 68 южноуральцев обеспечены лекарствами | - |
| 13.03.2024 | HIV prevention drugs known as PrEP are highly effective, but many at risk don't know about them | Despite highly effective HIV prevention drugs on the market, only a fraction of those at risk in the U.S. are taking them — or even know they're an option.
It's called pre-exposure prophylaxis, or PrEP, and it is about 99% effective to prev... |
| 12.03.2024 | Remdesivir (Veklury) Approval for the Treatment of COVID-19—The Evidence for Safety and Efficacy | Under FDA law, approval of a new drug requires substantial evidence of effectiveness and a demonstration of safety for the drug’s intended use(s). The approval of remdesivir (Veklury) for the treatment of patients hospitalized with COVID-19... |
| 11.03.2024 | Regenerative Medicine Industry Analysis and Outlook 2024-2034: Oncology Applications Lead the Forecasted $168 Billion Global Market | - |
| 11.03.2024 | Cell Therapy Market Insights Report: Collaboration and Licensing Deals 2016-2023 | - |
| 10.03.2024 | Blockbuster BeiGene Cancer Drug Adds Another FDA Approval | A BeiGene drug already used to treat several types of blood cancer now has an additional FDA approval as a treatment for follicular lymphoma. The regulatory decision makes the BeiGene drug the first in its class for treating this type of ca... |
| 08.03.2024 | Seladelpar (MBX-8025) Market Overview and Outlook 2024-2032: Product Overview, Regulatory Milestones, Global Activities, Patents, Market Assessment, Emerging Therapies, SWOT Analysis | - |
| 08.03.2024 | Hepatitis Drugs Market Size, Share And Growth Analysis For 2024-2033 | Hepatitis Drugs Market Report 2024 – Market Size, Trends, And Forecast 2024-2033
The Business Research Company has updated its global market reports with latest data for 2024 and projections up to 2033
The hepatitis drugs market size is exp... |
| 08.03.2024 | CAR T-Cell Therapy Market Set for Healthy Growth after COVID19 Pandemic Top Players Industry Trends and Forecast 2032 | CHICAGO, UNITED STATES, March 8, 2024 /EINPresswire.com/ -- Astute Analytica, a leading provider of market research and analysis, released its highly anticipated Market Analysis Report on the Global 𝐂𝐀𝐑 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭. This comprehen... |
| 06.03.2024 | HIV Injection Market to Reach $5.5 Billion, Globally By 2033 at 6.2% CAGR: Allied Market Research | - |
| 05.03.2024 | Infectious Diseases Collaborative Trends: Comprehensive Analysis of Biopharma Deals from 2016-2023 Unveiled | - |
| 08.02.2024 | Gilead sours on the ‘don’t eat me’ business | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with the latest Senate harangue for the drug industry, green shoots in biotech s... |
| 30.01.2024 | How an immunological Trojan horse could treat disease | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with some breathlessly anticipated news from Vertex Pharmaceuticals, an exit int... |
| 24.01.2024 | Incyte vets, with phase 1 within reach, raise $102M for new biotech to create better PARP, PI3K drugs | A group of familiar faces to Incyte watchers has broken off to start their own biotech, pulling in $102 million to develop competitors to approved cancer drugs from AstraZeneca, GSK, Novartis and Pfizer.
The biotech, Synnovation Therapeutic... |
| 29.11.2023 | GILEAD SCIENCES AWARDS OVER US$1.5 MILLION TO STRENGTHEN SUPPORT FOR COMMUNITY-LED HIV PROJECTS IN ASIA PACIFIC | –2023 Gilead Asia Pacific Rainbow Grant Funding Will Support 40 Projects In 2024-2025 To Reduce HIV Stigma And Improve Equity Across Asia Pacific –
– Since 2018, The Gilead Asia Pacific Rainbow Grant Has Awarded Close To US$6 Million To 144... |
| 15.11.2023 | The apparently strong correlation between biotech stocks and the price of eggs, explained | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with some annoyingly good news for the biotech market, a look at the plight of the Ph.D... |
| 08.11.2023 | BioMarin’s new CEO inherits a profitable company, a pioneering gene therapy, and a brewing activist challenge | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with a close look at an en-vogue idea in oncology, an awkward welcome for a new CEO, an... |
| 18.10.2023 | Health | PrEP, a key HIV prevention tool, isn’t reaching black women | Sam Whitehead | (TNS) Kaiser Health News
Alexis Perkins thought her OB-GYN’s office in Atlanta would be just the place to get a prescription for the type of drug that reduces a person’s risk of contracting HIV.
But during a recent visit, th... |
| 17.10.2023 | As Pfizer slashes revenue projections, Moderna says it “remains comfortable” | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with the latest twist in the GLP-1 saga, some drama in the world of Covid-19 booster sh... |
| 11.09.2023 | Gilead Delayed Introduction Of New Version of HIV Drug, With Fewer Side Effects, Maximizing Its Patent Monopoly And Profits | Techdirt has been writing about “evergreening” for many years. It refers to the practice by pharmaceutical companies of making small changes to a drug, often about to come off patent, in order to gain a new patent that extends its manufactu... |
| 28.07.2023 | GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION'S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030 | – Gilead expands the ALL4LIVER Grant, Providing Grant Funding to Organizations in Africa, South America, Asia and Oceania, Europe and North America –
– Themed 'Test. Link. Prioritize', the Grant Program will Target Projects Focusing on Vira... |
| 20.07.2023 | Genedata Announces Licensing Agreement with Gilead Sciences to Enhance Data Science Innovation in Discovery Research | Digitalizing Biopharma R&D Utilizing Genedata Profiler will enhance our capabilities for integration and analysis of large-scale multi-modal datasets as we continue to accelerate research for the discovery of transformative medicines. L... |
| 05.07.2023 | GILEAD SCIENCES AND IAS - THE INTERNATIONAL AIDS SOCIETY - HONOUR HEALTHCARE PROVIDERS GLOBALLY WHO CHAMPION STIGMA-FREE HIV SERVICES | — The 2023 Me and My Healthcare Provider (MMHCP) campaign, supported by Gilead for the second year running, honours frontline workers providing exemplary inclusive, stigma-free HIV services in Brazil, Hong Kong, Mexico and Taiwan —
— The IA... |
| 13.06.2023 | A-Alpha Bio Announces Collaboration With Gilead to Advance Next-Generation HIV Therapeutic Options | We are excited to collaborate with Gilead to advance the next generation of HIV therapies, drawing on our expertise in discovering and optimizing highly cross-reactive biologics
SEATTLE (PRWEB) June 13, 2023
A-Alpha Bio, a synthetic biology... |
| 01.05.2023 | GILEAD SCIENCES ANNOUNCES LAUNCH OF ASIA PACIFIC RAINBOW GRANT 2023 | –Gilead Sciences Celebrates the Fifth Anniversary Milestone of the Asia Pacific Rainbow Grant, with More Than US$4.5 Million Awarded to Organizations across the Asia Pacific Region to Date –
– Grant Program in 2023 Invites HIV-Focused Commu... |
| 18.03.2023 | Public Advisory - Two lots of cystic fibrosis drug Cayston recalled due to the potential of cracked glass vials | OTTAWA, ON, March 18, 2023 /CNW/ -
Summary Product: Gilead Sciences, Inc., Cayston (Lots 032168 and 033357) Issue: Health product – Product quality What to do: Check the lot number on your product or contact your pharmacist to determine whe... |
| 28.02.2023 | These 13 beaten-down stocks offer a 'margin of safety' from a possible credit shock, according to a top-1% fund manager | James Abate is the CIO of Centre Asset Management and the manager of its top-performing American Select Equity fund. Centre Asset Management This story is available exclusively to Insider subscribers. Become an Insider and start reading now... |
| 15.02.2023 | GILEAD TO PRESENT DATA AT APASL 2023 ON EFFECTIVE MODELS FOR MONITORING AND TREATING HEPATITIS C AND EFFICACY OF ANTIVIRAL TREATMENTS FOR HIV-1 AND HBV-COINFECTED ADULTS | - Study recommends a simplified strategy for baseline testing and minimal monitoring for treatment of hepatitis C virus (HCV) infection with DAA Therapies
- Review of implementation science projects toward HCV Elimination by 2030 in Asia pr... |
| 10.02.2023 | Antiviral Drugs Market Size is Estimated to be Valued at $ 75,558.0 Mn in 2030 | GlaxoSmithKline, AbbVie, Gilead Science | Antiviral Drugs Market
BURLINGAME, CALIFORNIA, UNITED STATES, February 10, 2023 /EINPresswire.com/ -- New Research Study “”Antiviral Drugs Market 2022 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and I... |
| 04.02.2023 | Gilead Sciences and 9 More Companies That Boosted Their Dividends This Week | Gilead Sciences Intercontinental Exchange and Old Dominion Freight Line were among the large U.S. companies that announced dividend increases this week.
Gilead Sciences (ticker: GILD), a biopharmaceutical company, declared a quarterly distr... |
| 20.12.2022 | Gilead Data Raise New Questions About Cancer Therapy | New data on a cancer drug trial from Gilead Sciences and Arcus Biosciences are resurfacing debate around the class of cancer drugs known as anti-TIGITs, and raising new questions about the future of a once-promising area of cancer drug deve... |
| 19.12.2022 | A tiny biotech's experimental treatment for a silent disease that strikes millions just cleared a key hurdle and the stock is up more than 200% | Madrigal Pharmaceuticals is hoping to succeed where others have failed in treating NASH, a serious liver disease. Pramote Polyamate/Getty Images
Madrigal Pharmaceuticals reported positive results in its phase 3 trial for a drug to treat NAS... |
| 09.12.2022 | Gilead Sciences Gets a Shot at Next-Gen Cell Therapy With $325M Arcellx Alliance | Gilead Sciences entered cell therapy with a multi-billion dollar acquisition that positioned it to compete with a Novartis treatment for blood cancers. Another deal now gives the drugmaker the opportunity to challenge Bristol Myers Squibb a... |
| 28.11.2022 | TELEHEALTH USAGE IN ASIA PACIFIC FOR PEOPLE LIVING WITH HIV INCREASING, BUT DATA PRIVACY AND LACK OF PERSONAL CONTACT STILL SEEN AS A BARRIER TO WIDER USE | - Half of the people living with HIV (PLHIV) and individuals at-risk (IARs) surveyed in the region increased their usage of telehealth services over the past year; this is driven by the availability of new telehealth services during pandemi... |
| 14.11.2022 | A top Wall Street analyst names 6 major events that could send biotech stocks soaring between now and the end of 2022 | Medical samples in vacutainer tubes held by a laboratory technician. Matthew Horwood/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Investors need to pay attentio... |
| 28.10.2022 | Gilead Sciences, Inc. Is Partnering with the ISPE Foundation to Establish a New Technology Without Borders Initiative | "My vision is to make the technology and information accessible and work with the key stakeholders in these regions so there is an ecosystem of people who can help support the further development and implementation of this knowledge,” ... |
| 19.10.2022 | Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity | Gilead Foundation's Creating Possible Fund™ Reflects Broad and Ongoing Commitment to Health Equity
Funding Will Support 13 U.S. Organizations Focused on Addressing Education Equity and Building a Pipeline of Black Health Leaders
FOSTER CITY... |
| 13.10.2022 | Gilead and the IAS start second year of partnership to honor champions of stigma-free HIV care services in Asia and Latin America | SINGAPORE, Oct. 13, 2022 /PRNewswire/ -- Gilead Sciences, Inc. and IAS – the International AIDS Society – have renewed their Me and My Healthcare Provider partnership to expand the campaign in Brazil, Hong Kong, Mexico, South Korea and Taiw... |
| 29.09.2022 | Gilead names 'kingpins' in counterfeit HIV med lawsuit | Gilead is mounting its counterfeit drug lawsuit, naming two “kingpins” and a complex network of conspirators who allegedly sold imitation bottles of its HIV meds, some of which ended up in US pharmacies.
The pharma gia... |
| 26.09.2022 | Digital health news, funding roundup in the prior week; September 26, 2022 | Therabody raised $165M; Walgreens bought Shields Health; UnitedHealthcare and Peloton partnered
Top Health News
Meru Health, an online mental health provider that combines science and technology, partnered with Curebase, an end-to-end clini... |
| 15.09.2022 | GILEAD SCIENCES CELEBRATES TOP RANKING BY HEPATITIS & ASIAN PATIENT GROUPS | -- In the recently published PatientView report, Gilead is ranked number one in all corporate reputation indicators by hepatitis patient groups globally --
-- Gilead also ranks first among peers in Asia by patient groups in this region --
H... |
| 25.08.2022 | Women in the Enterprise of Science & Technology (WEST) Announces Partnership with Operations Team at Gilead Sciences, Inc. | “At Gilead Sciences, we believe a diverse workforce is critical to creating a better, healthier world,” said Joydeep Ganguly, Senior Vice President, Corporate Operations at Gilead Sciences."
BOSTON (PRWEB) August 25, 2022
Women in the ... |
| 16.08.2022 | Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories | Everest to receive total considerations of up to $455 million with $280 million in upfront payments
Broadens development and access to Trodelvy for patients in Greater China and certain Asia Pacific Markets
Strengthens balance sheet and str... |
| 16.08.2022 | Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories | Everest to receive total considerations of up to $455 million with $280 million in upfront payments
Broadens development and access to Trodelvy for patients in Greater China and certain Asia Pacific Markets
Strengthens balance sheet and str... |
| 15.08.2022 | Gilead Data on Breast Cancer Drug Is ‘Surprise Win,’ Analyst Says | Gilead Sciences provided a much-awaited update on the trial of its breast cancer drug Trodelvy, prompting an RBC analyst to push his price target on the stock higher.
Gilead (ticker: GILD) announced Monday that the overall survival rate for... |
| 05.08.2022 | This Week in European Tech: Auxmoney lands €500 million, Glofox's €200 million acquisition, Germany's 'Future Fund' evolves, EU to set up shop in SF, and more
24 May in Brussels.
What happened this ... | This week, our research team tracked more than 65 tech funding deals worth over €1.1 billion (debt and equity) and over 20 exits, M&A transactions, rumours, and related news stories across Europe.
As always, we are putting all of them t... |
| 05.08.2022 | Gilead Sciences to Buy MiroBio, for $405M | Gilead Sciences, Inc. (Nasdaq: GILD), a Foster City, California-based biopharmaceutical company, is to acquire MiroBio, an Oxford, England, U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune ... |
| 04.08.2022 | Gilead Sciences to acquire Oxford University biotech spinout MiroBio for $405M | U.S. pharmaceutical giant Gilead Sciences has announced plans to acquire Oxford University biotech spinout company MiroBio in an all-cash deal worth $405 million.
MiroBio is a clinical-stage company focused on developing treatments to “rest... |
| 29.06.2022 | Gilead scores a $33M settlement from its campaign against ‘colossal financial fraud’ | More than 18 months and 860 court filings later, Gilead has bagged a new settlement in its campaign against a group of companies that participated in an alleged fraud aimed at its free meds program for people at risk of HIV.
G... |
| 28.06.2022 | Treatment Locator | Vulnerable populations at risk for severe COVID-19:
Certain populations are at greater risk of progressing to severe disease and warrant more significant consideration for prophylaxis or treatment.
Patients who are older (≥65 years), have c... |
| 16.06.2022 | GILEAD SCIENCES NEW DATA HIGHLIGHTS PEOPLE LIVING WITH HIV WHO ARE VIRALLY SUPPRESSED EXPERIENCE SIMILAR HEALTH-RELATED QUALITY OF LIFE AS GENERAL POPULATION | – Data in Taiwan Shows That Antiretroviral Therapies Have Helped Transform HIV Into a Chronic Condition and Bring Positive Change in the Outlook for People Living with HIV –
SINGAPORE, June 16, 2022 /PRNewswire/ -- Gilead Sciences, Inc. tod... |
| 06.06.2022 | GILEAD SCIENCES APPOINTS DUSTIN HAINES AS NEW LEADER FOR ASIA 5 REGION | -- Mr Haines Brings a Strong Track Record of Global Commercial Successes and Corporate Leadership with a Career that Spans 20 Years in Pharmaceuticals --
-- He Joins Gilead's Asia 5 Team as the Company Celebrates 10 Years of Presence in Asi... |
| 01.06.2022 | Pfizer’s Not-For-Profit Model For Sales Of Products To Low- And Lower-Middle-Income Countries May Be A Game Changer In Global Health | Pfizer CEO Albert Bourla gestures during a session at the World Economic Forum (WEF) annual meeting ... [+] in Davos on May 25, 2022. - Pfizer said it would sell its patented drugs at a not-for-profit basis to dozens of low- and lower-middl... |
| 08.05.2022 | This Week in European Tech: Auxmoney lands €500 million, Glofox's €200 million acquisition, Germany's 'Future Fund' evolves, EU to set up shop in SF, and more
24 May in Brussels.
What happened this ... | This week, our research team tracked more than 65 tech funding deals worth over €1.1 billion (debt and equity) and over 20 exits, M&A transactions, rumours, and related news stories across Europe.
As always, we are putting all of them t... |
| 19.04.2022 | GILEAD SCIENCES AND NATIONAL FOUNDATION OF DIGESTIVE DISEASES SET OUT TO STRENGTHEN LEARNING, ACCESS TO LIVER HEALTH EDUCATION IN SINGAPORE | -- Gilead Sciences supports National Foundation of Digestive Diseases with grant funding to improve liver health education in Singapore as part of its Asia Pacific ALL4LIVER Grant --
-- The National Foundation of Digestive Diseases gets dig... |
| 30.03.2022 | GILEAD ANNOUNCES NEW DATA REINFORCING CLINICAL BENEFITS OF ITS ANTIVIRAL TREATMENTS AMONG PEOPLE LIVING WITH HEPATITIS B AND C IN ASIA (APASL 2022) | Studies show potential improvement in risk of liver cancer in chronic hepatitis B patients after long-term antiviral treatment
Improved renal and bone parameters with tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TD... |
| 10.03.2022 | The Lowdown: Impossible Foods sues Motif FoodWorks over heme patent | Impossible Foods has sued fellow foodtech player Motif FoodWorks for patent infringement, in one of the highest-profile intellectual property (IP) disputes to date in the burgeoning alt-protein space.
In its complaint filed yesterday with t... |
| 07.03.2022 | Gilead Reports Success, but Offers Little Data, on Key Cancer Drug Trial | Gilead Sciences shares dropped sharply before recovering as the market opened, after a highly anticipated announcement of the results of a trial of the company’s breast cancer drug Trodelvy offered few details on its performance.
The compan... |
| 08.02.2022 | Gilead Sciences : Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities | Foster City, Calif., February 8, 2022 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced Veklury® (remdesivir) is available for ordering by all hospital and qualified non-hospital outpatient facilities. Access for this expanded patient ... |
| 04.02.2022 | Gilead Sciences : Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities | Foster City, Calif., February 4, 2022 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced Veklury® (remdesivir) is available for ordering by all hospital and qualified non-hospital outpatient facilities. Access for this expanded patient ... |
| 02.02.2022 | Gilead Sciences : Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare | Foster City, Calif., February 1, 2022 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has reached a global resolution with ViiV Healthcare for all pending or potential claims related to Gilead's sales of the HIV treatment... |
| 24.01.2022 | How can I get Paxlovid, the COVID-19 pill? Access to COVID treatments remains a challenge | Despite evidence showing the fast-spreading Omicron variant may pose a smaller risk of severe COVID-19 compared to the Delta variant, public health officials have warned for months that millions of Americans remain at high risk of severe il... |
| 24.01.2022 | Covid-19 roundup: FDA greenlights Gilead's Veklury for outpatient use; WHO head warns world is primed for more variants | The FDA has added to the label of Gilead’s Veklury — previously approved only for hospitalized patients above the age of 12 — to cover non-hospitalized adults, while also expanding the pediatric emergency use authoriz... |
| 19.01.2022 | Gilead Sciences : Announces Actions to Remove Counterfeit HIV Medications from U.S. Supply Chain | Foster City, Calif., January 19, 2021 - Gilead Sciencesannounced today that the company has taken action to protect the health and safety of the public from an expansive, criminal counterfeiting network responsible for distributing counterf... |
| 06.12.2021 | WHO recommends against the use of convalescent plasma for Covid-19 | All through this year you could practically feel the frustration of the biotech investor class as M&A activity continued to drag behind expectations — or desires. Buyouts of public companies provide the essential juice for keeping stock... |
| 06.12.2021 | Keytruda wins eighth FDA approval of 2021, moving into adjuvant and pediatric melanoma settings | Keytruda made history seven years ago as the first anti-PD-1 therapy approved in the US, winning an OK in metastatic melanoma. The drug has since become a megablockbuster, and on Friday earned a new approval in the field that... |
| 06.12.2021 | Even as boom wanes, a new $200M SPAC is still hoping for another big score | The biotech sector has been booming throughout the Covid-19 pandemic — and while it has slowed down considerably, there are yet more SPACs at work.
Blank check company BioPlus Acquisition Corp announced last Thursday that it... |
| 06.12.2021 | Seattle biotech closes $18M Series B — and acquires a company; Another George Church alum launches upstart | Seattle biotech Cyrus Biotechnology announced this morning that it closed an $18 million Series B — and landed an acquisition to boot.
The biotech, which has an in-house software program for biologics discovery, acquired... |
| 06.12.2021 | Biohaven shakes up leadership team as it feels the heat from migraine competitors | As Biohaven Pharma comes off a rollercoaster pipeline year, its CEO will take on more responsibility in a full C-suite makeover.
Matthew Buten
Vlad Coric was unanimously elected to the role of chairman of the board of direct... |
| 06.12.2021 | WHO recommends against the use of convalescent plasma for Covid-19 | Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up... |
| 06.12.2021 | Gilead recalls 2 lots of Veklury after investigation confirms complaint of glass particulates | Two lots of the Covid-19 treatment Veklury have been recalled by Gilead, the company said last week, after the appearance of glass particulates. A customer complaint was confirmed by Gilead’s investigation.
Veklury, also... |
| 06.12.2021 | WHO recommends against the use of convalescent plasma for Covid-19 | A British CDMO and the University of Manchester have teamed up to support the development of low-cost manufacturing of molnupiravir, the antiviral pill for Covid-19 that an FDA adcomm recommended for an EUA earlier this week.
Manchester’s I... |
| 06.12.2021 | WHO recommends against the use of convalescent plasma for Covid-19 | The World Health Organization said late today that it’s not recommending the use of convalescent plasma as a treatment for Covid-19 for mild or severe cases, but some U.S. experts disagree with the recommendations and s... |
